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Abstract
Despite the success of potent reverse transcriptase (RT) inhibitors against human
immunodeficiency virus type 1 (HIV-1) in combination regimens, the development of drug
resistant RTs constitutes a major hurdle for the long-term efficacy of current antiretroviral therapy.
Nucleoside β-triphosphate analogs of adenosine and nucleoside reverse transcriptase inhibitors
(NRTIs) (3′-azido-2′,3′-dideoxythymidine (AZT), 3′-fluoro-2′,3′-dideoxythymidine (FLT), and 2′,
3′-didehydro-2′,3′-dideoxythymidine (d4T)) were synthesized and their inhibitory activities were
evaluated against wild-type and multidrug resistant HIV-1 RTs. Adenosine β-triphosphate (1) and
AZT β-triphosphate (2) completely inhibited the DNA polymerase activity of wild type, the NRTI
multi resistant, and non-nucleoside RT inhibitors (NNRTI) resistant HIV-1 RT at 10 nM, 10 μM,
and 100 μM, respectively.
During HIV-1 replication, the viral RNA genome is reverse transcribed into an integrated
competent double stranded DNA by the virally encoded multifunctional enzyme reverse
transcriptase (RT).1 HIV-1 RT remains a prime target for continued development of
antagonists to inhibit virus replication and stem the devastating consequences of AIDS.
HIV-1 RT is a heterodimeric enzyme composed of 66 and 51 kD subunits (p66 and p51)
possessing RNA- and DNA-dependent DNA polymerase and RNase H activities.2 DNA
polymerase activity is essential for the synthesis of a RNA:DNA heteroduplex from the
single stranded viral RNA genome. RNase H hydrolyzes the RNA strand of the RNA:DNA
heteroduplex generated during reverse transcription and creates the primer for plus strand
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DNA synthesis. Thus, both DNA polymerase and RNase H activities of HIV-1 RT have
been considered as potential targets for antiretroviral therapy.3
Two classes of drugs belonging either to the nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) or to the non-nucleoside reverse transcriptase inhibitors (NNRTIs) have
been used in the clinic as part of the antiretroviral therapy against HIV/AIDS.4 NRTIs
compete with the natural deoxynucleoside triphosphates (dNTPs) during DNA synthesis and
act as chain terminators.5 In contrast, NNRTIs are non-competitive inhibitors that bind at an
allosteric nonsubstrate binding site, which is distinct from the substrate binding site of
HIV-1 RT.6 While the unique pharmacology of these inhibitors has rendered their use in
highly active antiretroviral therapy (HAART) therapy, HIV-1 has the ability to develop drug
resistance mutations for both NRTI and NNRTIs.7 Thus, design of novel lead compounds
that can inhibit wild-type and drug resistant HIV-1 RTs is a subject of major interest in
antiviral research.
Modified nucleoside triphosphates that mimic naturally occurring deoxyribo- and
ribonucleoside triphosphates have been used as probes in several biochemical pathways
involving DNA and RNA synthesis, and as potential diagnostic and therapeutic agents.8,9
The structural similarity of modified nucleotides to natural deoxyribo- and ribonucleoside
triphosphates makes them useful reagents as substrates or inhibitors for DNA or RNA
polymerases.10,11 A number of approaches have focused on modifications and/or
substitutions on the base,12,13 carbohydrate14-19 and linear triphosphate moieties20-25 to
design modified nucleotides for diverse applications in nucleic acid and antiviral research.
We have previously reported the synthesis of nucleoside 5′-O-α,β-methylene-β-
triphosphates and 5′-O-β,γ-methylenetriphosphates and their potency towards the enzymatic
function of wild-type HIV-1 RT.26,27 In continuation of our efforts to design a diverse array
of modified nucleoside triphosphates as RT inhibitors, we herein report the synthesis of
nucleoside β-triphosphate analogs (1–4) of adenosine and NRTIs, such as 3′-azido-3′-
deoxythymidine (zidovudine, AZT), 3′-fluoro-3′-deoxythymidine (alovudine, FLT), and 2′,
3′-didehydro-2′,3′-dideoxythymidine (stavudine, d4T) (Fig. 1) and their inhibitory activity
against the DNA polymerase of wild-type and multidrug resistant RTs. To the best of our
knowledge, this is the first report of the evaluation of nucleoside β-triphosphate analogs as
RT inhibitors.
The synthesis of a β-triphosphitylating reagent from phosphorus trichloride has been
previously reported by us in multi-step reactions.28 The reaction mixture containing β-
triphosphitylating reagent was immediately used in coupling reactions with polymer-bound
N-Boc p-acetoxybenzyl alcohol for the synthesis of a number of nucleoside β-
triphosphates.28 Our research on the solid-phase synthesis of organophosphorus and
organosulfur compounds revealed that the polymer-bound p-acetoxybenzyl alcohol
containing amide linker (5) was more stable than polymer-bound N-Boc p-acetoxybenzyl
alcohol even in basic conditions and was used to generate sulfonamides and other
organophosphorus compounds in high yields and without the need for extensive
purifications of final products.29,30 Thus, polymer-bound linker 5 instead of polymer-bound
N-Boc p-acetoxybenzyl alcohol was selected for the reaction with β-triphosphitylating
reagent 6 to generate a new polymer-bound β-triphosphitylating reagent 7 that was used for
preparation of nucleoside β-triphosphates including two novel compounds 3 and 4 (Scheme
1).
Scheme 1 shows the synthesis of nucleoside 5′-O-β-triphosphates (1–4). The aminomethyl
polystyrene resin-bound p-acetoxybenzyl alcohol (5, 3.85 g, 0.65 mmol/g) was subjected to
reaction with the β-triphosphitylating reagent (6, ∼10 mmol) in the presence of triethylamine
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(10 mmol) to produce the corresponding polymer-bound β-triphosphitylating reagent 7.
Unprotected nucleosides (e.g., adenosine (a), AZT (b), FLT (c), and d4T (d) were reacted
with polymer-bound reagent 7 in the presence of 5-(ethylthio)-1H-tetrazole to yield 8a–d.
Oxidation with t-butyl hydroperoxide followed by removal of the cyanoethoxy group with
DBU, afforded the corresponding polymer-bound nucleoside 5′-O-β-triphosphotriesters
(10a–d). The cleavage of polymer-bound compounds was carried out under acidic
conditions (TFA). The linker-trapped resin (12) was separated from the final products by
filtration. The crude products had a purity of 87-93% (Table 1) and were purified by using
small C18 Sep-Pak cartridges and appropriate solvents to afford nucleoside 5′-O-β-
triphosphates (1–4) in 76-90% overall yield (calculated from polymer-bound reagent 7 in the
four-step reaction sequence) (Table 1). Only one type of monosubstituted compound was
produced with high selectivity as a result of this sequence possibly because of the rigidity of
polymer-bound β-triphosphitylating reagent 7. In case of adenosine, the most reactive
hydroxyl group of unprotected nucleoside reacted selectively with hindered polymer-bound
reagent 7 when an excess of nucleoside was used. The chemical structures of the final
products (1–4) were determined by nuclear magnetic resonance spectra (1H NMR, 13C
NMR, and 31P NMR), high-resolution time-of-flight electrospray mass spectrometry, and
quantitative phosphorus analysis.
Enzyme p66/p51 HIV-1 RT was purified according to the protocol described by Le Grice et
al.31 DNA-synthesis was measured on 40 nt DNA template annealed to a 5′ end-labeled 22
nt DNA primer as described previously.32
The inhibitory effects of nucleoside β-triphosphate analogs 1–4 were evaluated against the
DNA polymerase activity of wild-type HIV-1 RT. The results of the inhibition assay are
presented in Fig. 2. Lane W represents the DNA polymerase activity of wild type HIV-1 RT
in the absence of any inhibitor, where the 32P-radiolabeled DNA primer was fully extended
to P+10. In the presence of the compounds 1–4, the DNA polymerase activity of HIV-1 RT
is greatly inhibited as reflected by the absence or reduced levels of P+10 bands (Fig. 2
panels A-D, lanes 1-6). β-Triphosphate analogs of adenosine (1) and AZT (2) completely
inhibited the DNA polymerase activity at 10 nM concentration (Fig. 2A and 1B, lane 1).
With β-triphosphate analogs of FLT (3) and d4T (4), DNA synthesis was severely reduced at
10-100 μM, but complete inhibition was not achieved at 1 mM concentration (Fig. 2C and
D, lanes 6). These data indicate that β-triphosphate analogs of adenosine and AZT are potent
inhibitors of wild-type HIV-1 RT. However, FLT and d4T analogs exhibit modest inhibitory
activity against HIV-1 RT. Thus, in addition to the modified triphosphate moiety, the nature
of nucleoside base is also significantly to optimal DNA polymerase inhibitory activity of
wild type RT.
Subsequently, we examined to determine whether these analogs have the ability to inhibit
NRTI resistant HIV-1 RT. To assess their inhibitory effects, we used the M184V/K65R/
Y115F RT. M184V confers high level resistance to lamivudine (3TC) and emtricitabine
(FTC), whereas the double mutant M184V/Y115F RT has decreased susceptibility to the
guanosine analogue, abacavir (ABC).33 Furthermore, K65R is associated with decreased
susceptibility to tenofovir (TFV). The results of DNA polymerase assays are presented in
Fig. 3. Lane W represents the DNA polymerase activity of M184V/K65R/Y115F RT in the
absence of any inhibitor. With compounds 1 and 2, a complete inhibition of M184V/K65R/
Y115F RT was achieved at 10 μM (Fig. 3 A-B, lane 4), although both compounds inhibited
wild-type HIV-1 RT at 10 nM concentrations (Fig. 2A-B). Surprisingly, compounds 3 and 4
completely inhibited the DNA polymerase activity of this enzyme at 100 μM (Fig. 3C and
3D, lane 5), even though they did not show similar potency against wild-type HIV-1 RT.
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The potency of these analogues against NNRTI resistant HIV-1 RT was also examined.
NNRTIs bind in a non-competitive manner to a specific pocket of the HIV-1 RT, which is
closely associated with, but distinct from, the substrate binding site. In our studies, we used
HIV-1 RT with Thymidine Associated Mutations (TAMs) that confer resistance to
NNRTIs.5 The results of the inhibitory activities of these compounds are presented in Fig. 4.
Overall the nucleoside β-triphosphate analogs (1–4) showed lower potency against NNRTI
resistant RTs in comparison to NRTI resistant RTs. Compounds 1 and 2 did not inhibit DNA
polymerase activity of NNRTI HIV-1 RT significantly at 10 nM-10 μM (Fig. 4 panels A-B,
lanes 1-4). However, they completely inhibited the NNRTI resistant RT at 100 μM (Fig. 4
panels A and B, lane 5). Although, compounds 3 and 4 impaired polymerase activity,
complete inhibition was not achieved at concentrations up to 1 mM (Fig. 4C and D, lane 6).
β-Triphosphates analogs of adenosine (1) and AZT (2) potently inhibited wild-type (10 nM)
and showed modest potency towards NRTI resistant RTs (10 μM) and NNRTI resistant RTs
(100 μM). On the other hand, compounds 3 and 4 inhibited most of DNA polymerase
activity of wild-type at 10-100 μM, but complete inhibition was not achieved at 1 mM,
suggesting that in addition to the β-triphosphate moiety, the nature of nucleotide base plays a
critical role in optimal wild type DNA polymerase inhibition. Interestingly, compounds 3
and 4 exhibited better potency towards NRTI resistant RTs (100 μM) when compared with
wild type RT (1 mM), indicating that the presence of a β-triphosphate moiety and the nature
of the base contribute to the inhibition of NRTI resistant RTs.
In case of NRTIs, drug resistance affects the binding and rate of incorporation of the
incoming nucleotide analog and primarily involves residues in direct contact with the
incoming NRTI triphosphate. These residues include K65R, L74V, Y115F, M184V/I, and
Q151M that cause steric hindrance to the proper binding of these inhibitors in the HIV RT
active site.34 In contrast, NNRTI resistant mutations (TAMs) in HIV-1 RT are located in the
allosteric site residues that prevent binding of the inhibitors. We assume that these
nucleoside β-triphosphate analogs have the ability to compete with the dNTP binding site of
HIV-1 RT, thereby conferring potent inhibitory activity against NRTI resistant RTs.
However, the potency of these analogs is limited towards the NNRTI resistant RT,
indicating that they cannot effectively bind to the allosteric site of the RT.
Our data revealed that, β-triphosphate analogs of adenosine and AZT were highly potent
against the wild-type and NRTI/NNRTI resistant RTs in comparison to the FLT and d4T
analogs. Thus, these analogs could potentially serve as lead molecules for designing
inhibitors that can inhibit an array of drug resistant HIV-1 RTs. Further investigations are
underway to determine the exact mechanism of inhibition of polymerase activity of wild
type and NRTI resistant HIV-1 resistant RT.
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Figure 1.
Chemical structures of nucleoside 5′-O-β-triphosphates (1–4).
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Figure 2.
DNA polymerase activity of HIV-1 RT. The 32P-radiolabeled primer is marked as P,
whereas the fully extended product is marked as P+10. Lane W represents DNA polymerase
activity in the absence of any inhibitor. DNA polymerase activities in presence of inhibitors
are presented in Panel A (compound 1), B (compound 2), C (compound 3), and D
(compound 4). Lane 1 (10 nM), lane 2 (100 nM), lane 3 (1 μM), lane 4 (10 μM), lane 5 (100
μM), and lane 6 (1 mM).
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Figure 3.
DNA polymerase activity of NRTI resistant HIV-1 RT mutant M184V/K65R/Y115F.
The 32P-radiolabeled primer is marked as P, whereas the fully extended product is marked
as P+10. Lane W represents DNA polymerase activity in the absence of any inhibitor. DNA
polymerase activities in presence of inhibitors are presented in Panel A (compound 1), B
(compound 2), C (compound 3), and D (compound 4). Lane 1 (10 nM), lane 2 (100 nM),
lane 3 (1 μM), lane 4 (10 μM), lane 5 (100 μM), and lane 6 (1 mM).
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Figure 4.
DNA polymerase activity of NNRTI Resistant HIV-1 RT. The 32P-radiolabeled primer is
marked as P, whereas the fully extended product is marked as P+10. Lane W represents
DNA polymerase activity in the absence of any inhibitor. DNA polymerase activities in
presence of inhibitors are presented in Panel A (compound 1), B (compound 2), C
(compound 3), and D (compound 4). Lane 1 (10 nM), lane 2 (100 nM), lane 3 (1 μM), lane 4
(10 μM), lane 5 (100 μM), and lane 6 (1 mM).
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Scheme 1.
Synthesis of polymer-bound β-triphosphitylating reagent 7 and nucleoside 5′-O-β-
triphosphates 1–4 using polymer-bound linker 5.
Dash et al. Page 11
Bioorg Med Chem Lett. Author manuscript; available in PMC 2012 June 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Dash et al. Page 12
Table 1
Overall isolated yields and purity of crude products for nucleoside 5′-O-β-triphosphates (1–4).
Compound Overall yield (%) calculated from 7 Purity of crude products (%)
1 82 87
2 90 93
3 85 91
4 76 88
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